• 1
    Johansson SG, Hourihane JO, Bousquet J et al.; EAACI (The European Academy of Allergology and Cinical Immunology) nomenclature task force. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56: 813824.
  • 2
    Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996;17: 185189.
  • 3
    Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 1994;330: 16631670.
  • 4
    Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998;317: 16241629.
  • 5
    International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. Allergy 1994;49: 134.
  • 6
    Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 1998;81: 463468.
  • 7
    White P, Smith H, Baker N, Davis W, Frew A. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy 1998;28: 266270.
  • 8
    Storms W, Meltzer EO, Nathan RA. Allergic rhinitis: the patient's perspective. J Allergy Clin Immunol 1997;99: S825S829.
  • 9
    Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999;104: 534540.
  • 10
    Global Strategy for Asthma Management and Prevention. WHO/NHLBI workshop report. In: National Institutes of Health, National Heart, Lung and Blood Institute, Publication Number 95-3659, 1995.
  • 11
    Langley GB, Sheppeard H. The visual analogue scale: its use in pain measurement. Rheumatol Int 1985;5: 145148.
  • 12
    Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85: 460472.
  • 13
    Yamagiwa M. Acoustic evaluation of the efficacy of medical therapy for allergic nasal obstruction. Eur Arch Otorhinolaryngol Suppl 1997;1: S82S84.
  • 14
    Morris S, Eccles R, Martez SJ, Riker DK, Witek TJ. An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion. Am J Rhinol 1997;11: 109115.
  • 15
    Lund VJ, Holmstrom M, Scadding GKS. Infectious rhinosinusitis in adults: classification, etiology and management. ENT J 1997;7684.
  • 16
    Ankier SI, Warrington SJ. A double-blind placebo-controlled study of the efficacy and tolerability of ebastine against hayfever in general practice patients. J Intern Med 1989;226: 453458.
  • 17
    Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 1996;1: 2025.
  • 18
    Bernstein DI, Creticos PS, Busse WW et al. Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996;97: 749755.
  • 19
    Day JH, Buckeridge DL, Clark RH, Briscoe MP, Phillips R. A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996;97: 10501057.
  • 20
    Jeal W, Faulds D. Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs 1997;53: 257280.
  • 21
    Alexander M. Comparative therapeutic studies with Tilavist. Allergy 1995;50: 2329.
  • 22
    Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;9: S742-S749.
  • 23
    Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996;98: 843845.
  • 24
    Stewart AL, Hays RD, Ware Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988;26: 724735.
  • 25
    Wiseman LR, Faulds D. Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996;51: 260277.
  • 26
    Vervloet D, Valleteau A. A double-blind placebo controlled study of the efficacy and safety of ebastine 20 mg, ebastine 10 mg and loratadine 10 mg in seasonal allergic rhinitis in Europe. Allergy 1999;54(suppl. 52):55.
  • 27
    Rosenthal R, Berger W, Bronsky E et al. Tri-Nasal triamcinolone acetonide nasal spray 200 and 400 micrograms qd versus placebo and Nasacort triamcinolone acetonide nasal aerosol 440 micrograms qd in patients suffering from seasonal allergic rhinitis during the grass season. Am J Rhinol 1998;12: 427433.
  • 28
    Wiseman LR, Benfield P. Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 1997;53: 885907.
  • 29
    Leino M, Ennavaara K, Latvala et al. Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic rhinitis. Clin Exp Allergy 1992;22: 929932.
  • 30
    Ahluwalia P, Anderson DF, McGill JI, Zakir R, Church MK. The effect of nedocromil sodium and levocabastine in the treatment of seasonal allergic conjunctivitis. Invest Vis Ophthalmol Sci 1999;40: S771.
  • 31
    Hingorani M, Lightman S. Therapeutic options in ocular allergic disease. Drugs 1995;50: 208221.
  • 32
    Jackson R, Feder G. Guidelines for clinical guidelines [editorial]. BMJ 1998;317: 427428.
  • 33
    Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 1999;318: 527530.
  • 34
    Dykewicz MS, Fineman S, Nicklas R et al. Joint task force algorithm and annotations for diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 1998;81: 469473.
  • 35
    Passali D, Mösges R. International conference on allergic rhinitis in childhood. Allergy 1999;54(suppl 55):44.
  • 36
    Van Cauwenberge P, Bachert C, Passalacqua G et al. EAACI Position paper. Consensus statement on the treatment of allergic rhinitis. Allergy 2000;55: 116134.
  • 37
    Juniper EF, Guyatt GH, Willan, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47: 8187.
  • 38
    Guyatt GH, King DR, Feeny DH, Stubbing D, Goldstein RS. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol 1999;52: 187192.
  • 39
    Ciprandi G, Canonica WG, Grosclaude M, Ostinelli J, Brazzola GG, Bousquet J. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 2002;57: 586591.